Trial Profile

Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen But Not Mechanical Ventilation

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 27 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Opaganib (Primary)
Indications COVID 2019 infections; Pneumonia
Focus Adverse reactions; Therapeutic Use
Acronyms Opaganib-RHB
Sponsors RedHill Biopharma

Most Recent Events

04 Aug 2020 Status changed from planning to not yet recruiting.
27 Jul 2020 New trial record
16 Jul 2020 According to a RedHill Biopharma media release, company has received approval from the Israeli Ministry of Health to initiate this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com